Question explored with the scientific record
Conversation so far
- 1 What is the best NOAC drug for long term use in a 69 yr old male in sinus Rythm with previous documented Atrial Fibrillation and two successful Cardioversion + a private exchange
- 2 What are the risks of taking 2000iu Nattokinase once a week in addition + a private exchange
- 3 What are the risks of stopping the NAOC + a private exchange
- 4 How is my stroke risk score used to decide whether to stop? + a private exchange
- 5 How useful are the QRIsk 2and 3 calculators for a 69yr old who is extremely fit and in excellent shape metabolic health + a private exchange
- 6 Are there better stroke-risk tools than CHA2DS2-VASc for AF?
- 7 What specific tests should I request from my GP. To get a comprehensive assessment of my metabolic profile
Answered on this page ↓
What specific tests should I request from my GP. To get a comprehensive assessment of my metabolic profile
The short version: you need a fasting insulin, not just glucose, and a lipid panel that includes triglycerides, not just total cholesterol. The rest depends on what your body is telling you.
A comprehensive metabolic assessment starts with what most GPs already order: a fasting glucose, a basic metabolic panel (BMP) for kidney function and electrolytes, and a lipid panel. But those miss the real story. The key addition is fasting insulin, which lets you calculate HOMA-IR, a direct measure of insulin resistance. Insulin resistance is the engine behind most metabolic disease, and it can be elevated years before glucose rises. A 2015 study of 372 type 2 diabetes patients found mean A1c was 7.38% and only 45.4% had good control, meaning the standard tests alone leave most people in the dark [3].
You also want a complete lipid panel that includes triglycerides and HDL, not just LDL and total cholesterol. The ratio of triglycerides to HDL is a strong marker of insulin resistance and small dense LDL particles, which are more atherogenic than the large fluffy kind. A 2014 study of 100 metabolic syndrome patients on rosuvastatin showed that treatment shifted LDL subfractions, but the standard lipid panel would not have caught it [1].
For liver health, add ALT and GGT. Nonalcoholic fatty liver disease is the most common liver condition in the developed world and is tightly linked to insulin resistance. A 2018 study of 212 type 2 diabetes patients found that ALT and GGT were significantly correlated with HOMA-IR [28]. The FIB-4 score, which combines age, platelets, ALT, and AST, can identify advanced fibrosis even when ALT is normal [20].
For kidney function, ask for cystatin C alongside creatinine. A 2013 NEJM study of over 90,000 people showed that cystatin C-based eGFR improved risk classification and mortality prediction compared to creatinine alone [7]. Creatinine is affected by muscle mass, diet, and hydration; cystatin C is not.
My call: fasting insulin, HOMA-IR, triglycerides, HDL, ALT, GGT, and cystatin C. That gives you the real metabolic picture. Confidence: high for the core tests (insulin, lipids, liver enzymes), moderate for cystatin C because it is not yet standard and may require out-of-pocket payment.
Sources used 5
-
Beneficial Effects of Rosuvastatin Treatment in Patients With Metabolic Syndrome
In 100 patients with metabolic syndrome, 6-month rosuvastatin 20 mg/day was associated with significant reductions in total cholesterol, LDL-C, oxidized LDL, fibrinogen, homocysteine, uric acid, HbA1c, and increases in HDL-C, but without a placebo control.
DOI: 10.1177/0003319714522107 -
Glycemic control and use of A1c in primary care patients with type 2 diabetes mellitus
Glycemic control among Spanish primary care patients with type 2 diabetes is suboptimal, with mean A1c 7.38% and only 45.4% achieving A1c <7%, accompanied by underuse of A1c testing (16% had no A1c in the prior year) and greater therapy intensity associated with worse control, i…
DOI: 10.1016/j.pcd.2015.01.006 -
Cystatin C versus Creatinine in Determining Risk Based on Kidney Function
This study demonstrates that incorporating cystatin C measurements into the estimation of glomerular filtration rate (eGFR) significantly improves the accuracy of chronic kidney disease risk classification and mortality prediction compared to creatinine-based eGFR alone.
DOI: 10.1056/NEJMoa1214234 -
Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?
This study evaluates the reliability of noninvasive fibrosis scoring systems in identifying advanced fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) who have normal alanine aminotransferase (ALT) levels, finding that the FIB-4 score is particularly effective i…
DOI: 10.1097/MEG.0b013e32835d72cf -
The Relationship Between Liver Enzymes and Insulin Resistance in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease
This study investigates the association between liver enzymes and insulin resistance in type 2 diabetes patients with non-alcoholic fatty liver disease (NAFLD), finding significant correlations that could aid in clinical evaluations and treatment strategies.
DOI: 10.1055/a-0603-7899